What is new?Using data from the large real-world CARdiovascular and DIABetes (CARDIAB) cohort, we identified a marked underutilization of SGLT2 inhibitors and GLP-1 receptor agonists among patients with type 2 diabetes and established cardiovascular disease. Here, SLC5A2 is linked to cardiovascular disorder.